United Therapeutics Releases Its First Corporate Responsibility Report
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its initial Corporate Responsibility Report with primarily 2019 data and selected 2020 highlights, providing stakeholders important information regarding the company's commitment to environmental, social, and governance (ESG) priorities.
"Environmental sensitivity and corporate responsibility have been part of our DNA since our inception," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "In light of growing interest in ESG from investors and other stakeholders, we are pleased to share our corporate responsibility achievements in this inaugural report."
United Therapeutics developed its initial Corporate Responsibility Report with guidance from members of its Board of Directors and the frameworks provided by both the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB). United Therapeutics is using applicable GRI and SASB metrics to measure its performance.
United Therapeutics plans to continue to report on its corporate responsibility efforts on an annual basis and plans to issue its next report around mid-year 2021.
Find the full report at corporateresponsibility.unither.com.
About United Therapeutics
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.
Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to our planned reporting on ESG matters, our ability to create value and sustain our success in the long-term, and our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of November 24, 2020 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.
For Further Information Contact:
Dewey Steadman at (202) 919-4097
SOURCE United Therapeutics Corporation